AGN up +1.34% percent Today $AGN High is at 213.60
Post# of 53537
Posted On: 11/18/2014 11:19:05 AM
AGN up +1.34% percent Today $AGN High is at 213.60 and the Low 207.18 with current volume of 2,404,220.
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 8 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), EOG: 97.14 (+0.79), HAL: 49.70 (+0.47), HP: 77.64 (-0.61), MRO: 31.90 (+0.08), BHI: 65.92 (+0.69)
Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics
PR Newswire - 1 hr 48 mins ago
Today, Zacks Investment Ideas feature highlights Features: Allergan (NYSE:AGN-Free Report), Actavis (NYSE:ACT-Free Report), Sketchers (NYSE:SKX-Free Report) and Zeltiq Aesthetics (Nasdaq:ZLTQ-Free Report).
AGN: 211.90 (+2.70)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 45 mins ago
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64)
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - Tue Nov 18, 6:55AM CST
Allergan (AMEX:AGN) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $209.20 on volume of 19.1 million shares, above average daily volume of 2.7 million. In the past 52 weeks, Allergan share prices have been bracketed by a low of $94.98 and a high of $213.91 and closed yesterday at $209.20, 120% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.2%.
AGN: 211.90 (+2.70)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.85 (+0.94), BIIB: 305.27 (+2.85), GE: 26.88 (+0.27), NKE: 95.96 (-0.10), HAL: 49.71 (+0.48), TSN: 42.28 (-0.75), GSAT: 2.59 (-0.21), LULU: 44.97 (+0.55), AGN: 211.90 (+2.70), MACK: 8.85 (+0.23), WHR: 176.68 (+1.13), UA: 68.94 (+0.05), DSX: 7.84 (+0.02), ALNY: 91.22 (+2.24), MPC: 93.04 (+0.53), JCP: 7.32 (+0.06), SHW: 240.45 (+1.14), MBLY: 47.87 (+0.89), REGN: 410.99 (+11.34), BHI: 65.92 (+0.69)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), V: 250.25 (+0.45), ALXN: 190.04 (+3.26), CTSH: 52.81 (-0.25), MA: 83.52 (+0.32), ADS: 282.76 (+1.88)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 211.90 (+2.70), MRK: 59.76 (+0.30), ABBV: 65.77 (+0.73), BMY: 58.75 (+0.32)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), AMAG: 36.40 (+1.64), BMY: 58.75 (+0.32)
NYSE stocks posting largest volume increases
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
AGN: 211.90 (+2.70), HAL: 49.71 (+0.48), BLT: 16.61 (+0.44), DKL: 40.30 (+0.30), BHI: 65.93 (+0.70)
Watch for Allergan to Potentially Pullback After Gaining 5.21% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 4:28PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.44 to a high of $213.91. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $200.60 on volume of 18.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 211.90 (+2.70)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), MRK: 59.76 (+0.30), VRX.TO: 159.79 (+5.39)
Halliburton and Allergan are big market movers
AP - Mon Nov 17, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.83 (+0.02), AGN: 211.90 (+2.70), HAS: 56.00 (-0.37), HAL: 49.71 (+0.48), DNR: 9.91 (-0.10), MITL: 10.26 (+0.06), FOLD: 6.37 (-0.33), BHI: 65.93 (+0.70)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), SAFM: 86.75 (+1.82), PPC: 31.24 (+0.30), MIK: 21.98 (+0.33), TSN: 42.28 (-0.75)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.52 (+4.47), HAS: 56.00 (-0.37), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), JIVE: 6.43 (+0.06), FB: 74.41 (+0.17), HAL: 49.71 (+0.48), DWA: 22.26 (-0.05), AGN: 211.90 (+2.70), LNKD: 224.55 (+1.27), BHI: 65.93 (+0.70), CRM: 63.06 (+0.55)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), LNKD: 224.55 (+1.27), FB: 74.41 (+0.17), HAL: 49.71 (+0.48), BHI: 65.93 (+0.70), Z: 117.40 (-0.46)
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
AGN: 211.90 (+2.70), GE: 26.88 (+0.27), F: 15.29 (-0.25), PFE: 30.54 (+0.22), HAL: 49.71 (+0.48), BAC: 17.20 (+0.11), DNR: 9.91 (-0.10), TWTR: 40.55 (+0.08), BHI: 65.93 (+0.70)
Fitch: Allergan Purchase by Actavis Would Pressure Ratings
Business Wire - Mon Nov 17, 12:44PM CST
Allergan's ratings remain on Rating Watch Negative following Actavis plc's (Actavis) announcement that it plans to acquire Allergan for approximately $66 billion. Allergan presently has $2.1 billion of outstanding debt.
AGN: 211.90 (+2.70)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 211.90 (+2.70), HAS: 56.00 (-0.37), AMZN: 327.52 (+4.47), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), LNKD: 224.55 (+1.27), JIVE: 6.43 (+0.06), FB: 74.40 (+0.16), HAL: 49.71 (+0.48), DWA: 22.26 (-0.05), CRM: 63.06 (+0.55), BHI: 65.93 (+0.70)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53)
Recent News posted below.
Allergan Inc AGN other info.
http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Stock Market News for November 18, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - 1 hr 8 mins ago
Markets ended its choppy run yesterday on a mixed note after Japan unexpectedly slipped into a recession
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), EOG: 97.14 (+0.79), HAL: 49.70 (+0.47), HP: 77.64 (-0.61), MRO: 31.90 (+0.08), BHI: 65.92 (+0.69)
Zacks Investment Ideas feature highlights: Allergan, Actavis, Sketchers and Zeltiq Aesthetics
PR Newswire - 1 hr 48 mins ago
Today, Zacks Investment Ideas feature highlights Features: Allergan (NYSE:AGN-Free Report), Actavis (NYSE:ACT-Free Report), Sketchers (NYSE:SKX-Free Report) and Zeltiq Aesthetics (Nasdaq:ZLTQ-Free Report).
AGN: 211.90 (+2.70)
Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 45 mins ago
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64)
Downgrade Alert for Allergan (AGN)
Comtex SmarTrend(R) - Tue Nov 18, 6:55AM CST
Allergan (AMEX:AGN) was downgraded from Buy to Neutral at Guggenheim today. The stock closed yesterday at $209.20 on volume of 19.1 million shares, above average daily volume of 2.7 million. In the past 52 weeks, Allergan share prices have been bracketed by a low of $94.98 and a high of $213.91 and closed yesterday at $209.20, 120% above that low price. Over the past week, the 200-day moving average (MA) has gone up 0.8% while the 50-day MA has advanced 1.2%.
AGN: 211.90 (+2.70)
Jim Cramer's 'Mad Money' Recap: When Bad News Is Really Good News for Us
at The Street - Mon Nov 17, 7:09PM CST
Cramer says this morning's losses and afternoon's gains prove that not all markets need to trade in tandem.
CST: 42.85 (+0.94), BIIB: 305.27 (+2.85), GE: 26.88 (+0.27), NKE: 95.96 (-0.10), HAL: 49.71 (+0.48), TSN: 42.28 (-0.75), GSAT: 2.59 (-0.21), LULU: 44.97 (+0.55), AGN: 211.90 (+2.70), MACK: 8.85 (+0.23), WHR: 176.68 (+1.13), UA: 68.94 (+0.05), DSX: 7.84 (+0.02), ALNY: 91.22 (+2.24), MPC: 93.04 (+0.53), JCP: 7.32 (+0.06), SHW: 240.45 (+1.14), MBLY: 47.87 (+0.89), REGN: 410.99 (+11.34), BHI: 65.92 (+0.69)
Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), V: 250.25 (+0.45), ALXN: 190.04 (+3.26), CTSH: 52.81 (-0.25), MA: 83.52 (+0.32), ADS: 282.76 (+1.88)
Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 211.90 (+2.70), MRK: 59.76 (+0.30), ABBV: 65.77 (+0.73), BMY: 58.75 (+0.32)
Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), AMAG: 36.40 (+1.64), BMY: 58.75 (+0.32)
NYSE stocks posting largest volume increases
AP - Mon Nov 17, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
AGN: 211.90 (+2.70), HAL: 49.71 (+0.48), BLT: 16.61 (+0.44), DKL: 40.30 (+0.30), BHI: 65.93 (+0.70)
Watch for Allergan to Potentially Pullback After Gaining 5.21% Yesterday
Comtex SmarTrend(R) - Mon Nov 17, 4:28PM CST
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $207.44 to a high of $213.91. Yesterday, the shares gained 5.2%, which took the trading range above the 3-day high of $200.60 on volume of 18.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN: 211.90 (+2.70)
Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), MRK: 59.76 (+0.30), VRX.TO: 159.79 (+5.39)
Halliburton and Allergan are big market movers
AP - Mon Nov 17, 3:33PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
EXH: 36.83 (+0.02), AGN: 211.90 (+2.70), HAS: 56.00 (-0.37), HAL: 49.71 (+0.48), DNR: 9.91 (-0.10), MITL: 10.26 (+0.06), FOLD: 6.37 (-0.33), BHI: 65.93 (+0.70)
Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), SAFM: 86.75 (+1.82), PPC: 31.24 (+0.30), MIK: 21.98 (+0.33), TSN: 42.28 (-0.75)
Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 327.52 (+4.47), HAS: 56.00 (-0.37), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53), JIVE: 6.43 (+0.06), FB: 74.41 (+0.17), HAL: 49.71 (+0.48), DWA: 22.26 (-0.05), AGN: 211.90 (+2.70), LNKD: 224.55 (+1.27), BHI: 65.93 (+0.70), CRM: 63.06 (+0.55)
Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 211.90 (+2.70), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), LNKD: 224.55 (+1.27), FB: 74.41 (+0.17), HAL: 49.71 (+0.48), BHI: 65.93 (+0.70), Z: 117.40 (-0.46)
Most active New York Stock Exchange-traded stocks
AP - Mon Nov 17, 1:22PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at 1 p.m.:
AGN: 211.90 (+2.70), GE: 26.88 (+0.27), F: 15.29 (-0.25), PFE: 30.54 (+0.22), HAL: 49.71 (+0.48), BAC: 17.20 (+0.11), DNR: 9.91 (-0.10), TWTR: 40.55 (+0.08), BHI: 65.93 (+0.70)
Fitch: Allergan Purchase by Actavis Would Pressure Ratings
Business Wire - Mon Nov 17, 12:44PM CST
Allergan's ratings remain on Rating Watch Negative following Actavis plc's (Actavis) announcement that it plans to acquire Allergan for approximately $66 billion. Allergan presently has $2.1 billion of outstanding debt.
AGN: 211.90 (+2.70)
Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 211.90 (+2.70), HAS: 56.00 (-0.37), AMZN: 327.52 (+4.47), VRX: 141.26 (+4.53), ACT: 260.58 (+12.64), LNKD: 224.55 (+1.27), JIVE: 6.43 (+0.06), FB: 74.40 (+0.16), HAL: 49.71 (+0.48), DWA: 22.26 (-0.05), CRM: 63.06 (+0.55), BHI: 65.93 (+0.70)
Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST
AGN: 211.90 (+2.70), ACT: 260.58 (+12.64), VRX: 141.26 (+4.53)
(0)
(0)